MP45-09 CANCER SURVIVORSHIP IN MALE PATIENTS: THE IMPORTANCE OF INVOLVING THE ANDROLOGIST IN THE REAL-LIFE WORLD

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP45-09 CANCER SURVIVORSHIP IN MALE PATIENTS: THE IMPORTANCE OF INVOLVING THE ANDROLOGIST IN THE REAL-LIFE WORLD Simone Cilio, Edoardo Pozzi, Federico Belladelli, Giuseppe Fallara, Luigi Candela, Alessandro Bertini, Christian Corsini, Francesco Lanzaro, Donato Cannoletta, Massimiliano Raffo, Fausto Negri, Ludovica Cella, Margherita Fantin, Luca Boeri, Paolo Capogrosso, Alessia D'arma, Francesco Montorsi, and Andrea Salonia Simone CilioSimone Cilio More articles by this author , Edoardo PozziEdoardo Pozzi More articles by this author , Federico BelladelliFederico Belladelli More articles by this author , Giuseppe FallaraGiuseppe Fallara More articles by this author , Luigi CandelaLuigi Candela More articles by this author , Alessandro BertiniAlessandro Bertini More articles by this author , Christian CorsiniChristian Corsini More articles by this author , Francesco LanzaroFrancesco Lanzaro More articles by this author , Donato CannolettaDonato Cannoletta More articles by this author , Massimiliano RaffoMassimiliano Raffo More articles by this author , Fausto NegriFausto Negri More articles by this author , Ludovica CellaLudovica Cella More articles by this author , Margherita FantinMargherita Fantin More articles by this author , Luca BoeriLuca Boeri More articles by this author , Paolo CapogrossoPaolo Capogrosso More articles by this author , Alessia D'armaAlessia D'arma More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , and Andrea SaloniaAndrea Salonia More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003291.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Male cancer survivors may develop sexual dysfunction (SD) even many years after the recovery from the original malignant disease. An andrological assessment of these patients is not routinely provided in the everyday clinical practice. We aimed to evaluate the prevalence of and the clinical characteristics of cancer survivors in a cohort of men seeking medical help for SD (any) in the real-life setting of an andrological tertiary-referral centre. METHODS: Complete data from 2841 men consecutively assessed for new-onset SD between 2005 and 2022 were analysed. All patients were assessed with a comprehensive sexual and medical history, including history of any non-metastatic cancer (i.e., urological cancers, non-urological solid cancers, haematological cancer). All patients were invited to complete the International Index of Erectile Function (IIEF), and the Beck’s Depression Index (BDI). The IIEF-Erectile function (IIEF-EF) domain was categorized according to Cappelleri’s criteria. RESULTS: Of all, 237 (8.34%) patients reported a history of non-metastatic cancer, either solid or haematological. Of 237, 118 (49.8%) patients had a history of urological cancer, 92 (38.8%) of non-urological solid cancer, and 27 (11.4%) of haematological malignancies. Overall, the most frequent complaint was ED (76.4% of patients), followed by Peyronie’s disease (PD) (13.9%), low sexual desire/interest (LSD/I) (13.5%), premature ejaculation (PE) (6.8%), and delayed ejaculation (2.1%). Moreover, the most frequent concurrent complaints were ED and LSD/I reported together by 11.4% of patients, followed by ED and PD reported by 8.4% of patients. Of all, prostate cancer (PCa) survivors accounted for 41.0% of solid cancer survivors and 37.1% of the whole cohort. The most frequent non-urological cancer was colorectal cancer (CRC), reported by 10.6% of patients. Men with a history of either PCa or CRC complained more of ED [98 (92.5%) vs .68 (62.4%) men; p=0.001] and had lower rates of normal IIEF-EF [1 (0.9%) vs. 6 (5.5%) men; p=0.03], with respect to patients with a history of other types of cancers, whom conversely reported higher rates of PE [4 (3.8%) vs. 12 (11%) men; p=0.03] and of PD [9 (8.5%) vs. 21 (19.3%) men; p=0.007]. CONCLUSIONS: Almost 10% of men seeking first medical help for SD in a tertiary-referral andrology centre are cancer survivors. Following the improvement of survivorship rates in male patients, an andrological assessment should always be included throughout the follow-up of cancer survivors. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e624 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Simone Cilio More articles by this author Edoardo Pozzi More articles by this author Federico Belladelli More articles by this author Giuseppe Fallara More articles by this author Luigi Candela More articles by this author Alessandro Bertini More articles by this author Christian Corsini More articles by this author Francesco Lanzaro More articles by this author Donato Cannoletta More articles by this author Massimiliano Raffo More articles by this author Fausto Negri More articles by this author Ludovica Cella More articles by this author Margherita Fantin More articles by this author Luca Boeri More articles by this author Paolo Capogrosso More articles by this author Alessia D'arma More articles by this author Francesco Montorsi More articles by this author Andrea Salonia More articles by this author Expand All Advertisement PDF downloadLoading ...